PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.

Trial Details

NCT ID
NCT05440227
Phase
PHASE2
Sponsor
PhytoHealth Corporation
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • PG2 Lyo. Injection 500mg
  • Placebo 0.9% normal saline
Locations (sample)
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Women aged ≥ 20 years
  • ECOG performance score ≤ 2
  • Locally advanced, recurrent or metastatic, histologically documented breast cancer who is currently undergoing infusional chemotherapy regimen.
  • Presence of moderate to severe cancer related fatigue prior to randomization as defined by at least two records of usual fatigue score ≥ 4 on the n…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →